Skip to main content

Generics

  • Ranbaxy launches generic Aricept

    GURGAON, India, and PRINCETON, N.J. — Ranbaxy Pharmaceuticals has received final approval for its generic Alzheimer's drug from the Food and Drug Administration, giving the drug maker 180 days of market exclusivity.

    Ranbaxy Pharmaceuticals, a subsidiary of Ranbaxy Labs, will manufacture and market donepezil hydrochloride tablets, a generic version of Aricept, in the 5-mg and 10-mg strength in the United States.

  • Impax confirms patent challenge for generic Concerta

    HAYWARD, Calif. — A generic version of a drug indicated to treat attention deficit hyperactivity disorder has hit a roadblock.

  • Perrigo, Synthon to launch generic Xyzal

    ALLEGAN, Mich. — The Food and Drug Administration has granted market exclusivity for a generic version of a medication designed to treat indoor and outdoor allergies.

    Perrigo said Monday that its licensor and supplier Synthon received regulatory approval for levocetirizine tablets, a generic version of UCB/Sepracor's Xyzal, which is marketed in the United States by Sanofi-Aventis.

    The levocetirizine tablet is the only approved generic product having a label containing all indications, Perrigo said.

  • Impax challenges Abbott's Simcor patent

    HAYWARD, Calif. — Generic drug maker Impax Labs is challenging the patent covering a drug used to treat high cholesterol, the company said Friday.

    Impax said it had filed an approval application with the Food and Drug Administration for niacin and simvastatin extended-release tablets in the 1,000 mg/20 mg strength. The drug is a generic version of Abbott Labs’ Simcor.

  • Walgreens' Pegus to discuss impact of diabetes management on healthcare costs

    DEERFIELD, Ill. — Walgreens' chief medical officer will discuss the evidence-based medicine design and impact of a diabetes management program delivered by pharmacists at both workplace and community pharmacies during an upcoming conference, the drug store chain said.

  • FDA tentatively approves Sun's generic Cymbalta

    MUMBAI, India — A generic drug maker announced that the Food and Drug Administration has granted tentative approval for its version of a popular antidepressant.

    Sun Pharmaceutical Industries said the FDA approved its duloxetine hydrochloride delayed-release capsules in 20-mg, 30-mg and 60-mg strengths. The capsules are a generic version of Eli Lilly's Cymbalta, which is indicated to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain.

  • UnitedHealthcare partners with Kroger, Safeway on $2 generic Part D plan

    MINNETONKA, Minn. — UnitedHealth Group will start a program next year that it said can reduce drug costs to as low as $2 per script, the company said Tuesday.

    The program, Pharmacy Saver, will be available to Medicare Part D members and is a collaboration with Kroger, Safeway and Prescription Solutions. The program will allow members to purchase some scripts for $2 for 30- and some 90-day supplies and applies to hundreds of prescription drugs, including 8-of-the-10 most commonly used by UnitedHealthcare Medicare plan members.

  • Antiviral drugs could cause insulin resistance, study finds

    ST. LOUIS — Since the beginning of the HIV/AIDS epidemic in the early 1980s, one of the greatest advances has been antiviral drugs that have helped extend the lives of patients with viral infections.

X
This ad will auto-close in 10 seconds